Lung Cancer
A randomized phase 2 platform study to evaluate cemiplimab plus chemotherapy versus cemiplimab plus chemotherapy plus other cancer treatments for the perioperative treatment of patients with resectable non-small cell lung cancer (R2810-ONC-2268)
- Details
ClinicalTrials.gov ID:
NCT06465329
Diagnosis Type:
NA
USOR Number:
- Address
,
P: